Lactiplantibacillus plantarum F3-2/Pet Probiotics powder

Products customized are acceptable.

Potency: 10B CFU/g, 50B CFU/g, 100B CFU/g, 200B CFU/g, 300B CFU/g, 400B CFU/g, 500B CFU/g 

Shelf life: 24 months

Storage conditions: Stored at -18℃or below

Lactobacillus plantarum F3-2 in combination with mannan oligosaccharide improves obesity in mice by inhibiting PPARγ through up-regulation of SCFAs’ This research paper investigates the effects of the combination of the probiotic Lactobacillus plantarum F3-2 with the prebiotic mannan oligosaccharide (MOS) on obese mice and analyses the underlying mechanisms.

 

Study Objectives

* To assess the effect of combined probiotic and prebiotic intervention on obesity.

* To investigate the mechanism of the combined action.

 

Research Methods

* Mice were divided into four groups: control group, high-fat diet group, MOS intervention group, and F3-2+MOS combined intervention group.

* After 6 weeks of intervention, body weight, adipose tissue weight, serum lipid level, adipocyte size, expression of key genes of lipid metabolism, and fecal levels of short-chain fatty acids (SCFAs) were measured.

 

Study Results

* Body weight and adipose tissue: The body weight, adipose tissue weight and adipocyte size of mice in the F3-2+MOS combined intervention group were significantly lower than those in the MOS alone intervention group, suggesting that the combined intervention was more effective in suppressing fat accumulation.

* Lipid levels: Serum triglyceride levels were significantly reduced after MOS intervention, while triglyceride levels were further reduced in the F3-2+MOS combined intervention group, suggesting that the combined intervention was more effective in improving lipid levels.

* Levels of SCFAs: Concentrations of acetic acid, propionic acid and butyric acid in faeces were significantly increased after MOS intervention, whereas the concentrations of these three SCFAs were further increased in the F3-2+MOS combined intervention group, especially the concentration of butyric acid was significantly increased.

* Expression of key genes for lipid metabolism: PPARγ and C/EBPα gene expression was significantly down-regulated in the adipose tissue of mice in the F3-2+MOS co-intervention group, suggesting that the co-intervention was more effective in inhibiting adipocyte differentiation.

 

Study Conclusion

* F3-2+MOS combined intervention can effectively improve obesity, and its mechanism may be through elevating the level of SCFAs, especially butyric acid, in feces, and then inhibiting the expression of key genes of lipid metabolism in adipose tissues, inhibiting adipocyte differentiation, and ultimately achieving the effect of reducing body weight and improving the level of blood lipids.

 

Research Implications

* Provides a new strategy for dietary intervention for obesity, i.e. the use of synbiotic products.

* Provides a theoretical basis for the development of novel weight loss products, such as probiotic drinks or foods containing F3-2 and MOS.

 

Research Outlook

* To explore in depth how F3-2 affects the level of SCFAs and other mechanisms of action.

* Evaluate the effects of F3-2+MOS on human obesity.

 

Summary

This study demonstrates the effectiveness of combined probiotic and prebiotic interventions in obesity and reveals the underlying mechanisms. This provides a theoretical basis for the development of novel weight loss products and new ideas for dietary intervention in obesity.